Journal ArticleDOI
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
Samba O. Sow,Brown J. Okoko,Aldiouma Diallo,Simonetta Viviani,Ray Borrow,George M. Carlone,Milagritos D. Tapia,Adebayo Akinsola,Pascal Arduin,Helen Findlow,Cheryl M. Elie,Fadima Cheick Haidara,Richard A. Adegbola,Doudou Diop,Varsha Parulekar,Julie Chaumont,Lionel Martellet,Fatoumata Diallo,Olubukola T. Idoko,Yuxiao Tang,Brian D. Plikaytis,Prasad S. Kulkarni,Elisa Marchetti,F. Marc LaForce,Marie-Pierre Préziosi +24 more
TLDR
The PsA-TT vaccine elicited a stronger response to group A antibody than the PsACWY vaccine, and had obvious immunologic memory after receiving a polysaccharide booster vaccine.Abstract:
Background Group A meningococci are the source of major epidemics of meningitis in Africa An affordable, highly immunogenic meningococcal A conjugate vaccine is needed Methods We conducted two studies in Africa to evaluate a new MenA conjugate vaccine (PsA-TT) In study A, 601 children, 12 to 23 months of age, were randomly assigned to receive PsA-TT, a quadrivalent polysaccharide reference vaccine (PsACWY), or a control vaccine (Haemophilus influenzae type b conjugate vaccine [Hib-TT]) Ten months later, these children underwent another round of randomization within each group to receive a full dose of PsA-TT, a one-fifth dose of PsACWY, or a full dose of Hib-TT, with 589 of the original participants receiving a booster dose In study B, 900 subjects between 2 and 29 years of age were randomly assigned to receive PsA-TT or PsACWY Safety and reactogenicity were evaluated, and immunogenicity was assessed by measuring the activity of group A serum bactericidal antibody (SBA) with rabbit complement and peread more
Citations
More filters
Journal ArticleDOI
Vaccines for the twenty-first century society.
TL;DR: Supporting by the innovations derived from new technologies, vaccines will address the new needs of a twenty-first century society characterized by increased life expectancy, emerging infections and poverty in low-income countries.
Journal ArticleDOI
The changing and dynamic epidemiology of meningococcal disease.
Scott A. Halperin,Julie A. Bettinger,Brian Greenwood,Lee H. Harrison,Jane Jelfs,Shamez N Ladhani,Peter McIntyre,Mary Ramsay,Marco Aurélio Palazzi Sáfadi +8 more
TL;DR: The imminent availability of recombinant broadly protective serogroups B vaccines may provide the tools for further control of invasive meningococcal disease in areas where serogroup B disease predominates.
Journal ArticleDOI
After 2015: infectious diseases in a new era of health and development.
TL;DR: Five aspects of the fight against infection beyond 2015 are highlighted, including exploiting the biological links between infectious and non-infectious diseases; controlling infections among the new urban majority; enhancing the response to international health threats; expanding childhood immunization programmes to prevent acute and chronic diseases in adults; and working towards universal health coverage.
Journal ArticleDOI
Effect of vaccines on bacterial meningitis worldwide
TL;DR: Despite greater than 90% reductions in disease attributable to vaccine serotypes, all-age pneumococcal meningitis has decreased by around 25%, with little data from low-income settings.
Journal ArticleDOI
Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study
Doumagoum M. Daugla,Jean Pierre Gami,Kadidja Gamougam,Nathan Naibei,Lodoum Mbainadji,Maxime Narbé,Jacques Toralta,B Kodbesse,C Ngadoua,Matthew E. Coldiron,Florence Fermon,A-L Page,Mamoudou Harouna Djingarey,Stéphane Hugonnet,Odile B. Harrison,Lisa S. Rebbetts,Yenenesh K. Tekletsion,Eleanor R. Watkins,Dorothea M. C. Hill,Dominique A. Caugant,Daniel Chandramohan,Musa Hassan-King,Olivier Manigart,Maria Claudia Nascimento,Arouna Woukeu,Caroline Trotter,James M. Stuart,Martin C. J. Maiden,Brian Greenwood +28 more
TL;DR: PSA–TT was highly effective at prevention of serogroup A invasive meningococcal disease and carriage in Chad and how long this protection will persist needs to be established.
References
More filters
Journal ArticleDOI
Comparative analysis of two rates
TL;DR: This paper examines comparative analysis of rates with a view to each of the usual comparative parameters-rate difference, rate ratio and odds ratio with particular reference to first principles, and stresses the need for restricted estimation of variance in the chi-square function underlying interval estimation.
Journal ArticleDOI
Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk.
TL;DR: This paper reviews some of the test statistics and sample size formulae proposed for comparative binomial trials when the null hypothesis is of a specified non-zero difference or non-unity relative risk.
Journal ArticleDOI
Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.
Susan E. Maslanka,Linda L. Gheesling,Daniel E. Libutti,Kimberley B. J. Donaldson,H S Harakeh,Janet K. Dykes,F F Arhin,S J Devi,C E Frasch,Jyh-Hsiung Huang,P Kriz-Kuzemenska,R D Lemmon,M Lorange,C C Peeters,Sally A. Quataert,J Y Tai,George M. Carlone +16 more
TL;DR: The standardized SBA was reliable in all laboratories regardless of experience in performing SBAs, and will facilitate interlaboratory comparisons of the functional antibody produced in response to current or developing serogroup A and C meningococcal vaccines.
Journal ArticleDOI
Meningococcal surrogates of protection--serum bactericidal antibody activity.
TL;DR: In this article, a review of the SBA activity as a correlate of protection for evaluating the immune response to meningococcal vaccines is described, and the proportions of vaccines with > or =4-fold rises in SBA pre-to-post-vaccination or SBA titres < or = 4 have been correlated with clinical efficacy in trials of outer membrane vesicle (OMV) vaccines in Cuba, Brazil and Norway.
Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays
Susan E. Maslanka,Linda L. Gheesling,Daniel E. Libutti,Kimberley B. J. Donaldson,Hani S. Harakeh,Janet K. Dykes,Francis F. Arhin,Sarvamangala J.N. Devi,Carl E. Frasch,Jay C. Huang,Paula Kriz-Kuzemenska,Robert D. Lemmon,Manon Lorange,Carla C. A. M. Peeters,Sally A. Quataert,Joseph Y. Tai,George M. Carlone +16 more
TL;DR: The specified assay, which includes the critical parameters of target strain, incubation time, and complement source, will facilitate interlaboratory comparisons of the functional antibody produced in response to current or developing serogroup A and C meningococcal vaccines.
Related Papers (5)
Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study
Doumagoum M. Daugla,Jean Pierre Gami,Kadidja Gamougam,Nathan Naibei,Lodoum Mbainadji,Maxime Narbé,Jacques Toralta,B Kodbesse,C Ngadoua,Matthew E. Coldiron,Florence Fermon,A-L Page,Mamoudou Harouna Djingarey,Stéphane Hugonnet,Odile B. Harrison,Lisa S. Rebbetts,Yenenesh K. Tekletsion,Eleanor R. Watkins,Dorothea M. C. Hill,Dominique A. Caugant,Daniel Chandramohan,Musa Hassan-King,Olivier Manigart,Maria Claudia Nascimento,Arouna Woukeu,Caroline Trotter,James M. Stuart,Martin C. J. Maiden,Brian Greenwood +28 more